Double maintains 3 strategies that include PCRX - Pacira Biosciences, Inc.
Current Value
$24.671 Year Return
Current Value
$24.671 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | 0.06% | $195.31M | 0.85% |
IBMO | 0.10% | $506.25M | 0.18% |
SLQD | 0.10% | $2.23B | 0.06% |
OILK | 0.10% | $67.99M | 0.69% |
FLTR | -0.11% | $2.42B | 0.14% |
IVOL | 0.14% | $477.82M | 1.02% |
SCHJ | 0.15% | $515.19M | 0.03% |
IBDQ | 0.16% | $3.18B | 0.1% |
IBDS | -0.16% | $2.96B | 0.1% |
DBO | 0.22% | $202.31M | 0.77% |
UPAR | -0.26% | $64.13M | 0.65% |
CLSE | -0.27% | $169.42M | 1.55% |
IBTG | -0.27% | $1.82B | 0.07% |
SPIB | -0.28% | $9.71B | 0.04% |
HNDL | 0.31% | $698.08M | 0.97% |
UCON | 0.35% | $3.46B | 0.85% |
DBB | -0.35% | $123.76M | 0.77% |
JBBB | -0.36% | $1.74B | 0.49% |
EMLC | -0.37% | $2.75B | 0.3% |
IBMR | 0.39% | $222.42M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DHI | 0.01% | $40.15B | -18.14% | 1.11% |
CAMT | 0.01% | $2.70B | -28.08% | 0.00% |
PAAS | 0.01% | $9.27B | +62.13% | 1.57% |
XOS | -0.02% | $24.25M | -64.64% | 0.00% |
PRPO | 0.02% | $8.50M | -12.81% | 0.00% |
TSM | 0.02% | $874.55B | +20.27% | 1.47% |
CI | -0.03% | $89.74B | -8.84% | 1.73% |
NRDS | 0.03% | $691.43M | -33.12% | 0.00% |
REG | -0.06% | $13.35B | +23.29% | 3.76% |
GSHD | 0.07% | $2.95B | +88.08% | 0.00% |
TSN | 0.08% | $22.04B | +9.57% | 3.13% |
SBRA | 0.09% | $4.16B | +19.86% | 6.88% |
EQIX | 0.10% | $79.52B | +3.06% | 2.15% |
BBDO | 0.10% | $11.17B | -10.51% | 1.75% |
FARO | -0.11% | $520.48M | +31.38% | 0.00% |
MMC | 0.12% | $119.84B | +20.15% | 1.30% |
CION | -0.12% | - | - | 13.85% |
AMP | -0.12% | $46.82B | +12.81% | 1.21% |
SVM | -0.12% | $834.88M | +8.78% | 0.66% |
NHTC | 0.12% | $58.60M | -27.29% | 15.72% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | -14.48% | $691.33M | 0.14% |
TAXF | -13.91% | $516.85M | 0.29% |
MMIN | -13.14% | $472.94M | 0.3% |
TFLO | -12.25% | $6.78B | 0.15% |
JMST | -11.42% | $3.55B | 0.18% |
BSMW | -10.85% | $100.91M | 0.18% |
DBA | -10.79% | $818.93M | 0.93% |
PWZ | -10.34% | $700.01M | 0.28% |
PZA | -9.91% | $2.97B | 0.28% |
IBTP | -9.65% | $109.02M | 0.07% |
MUST | -9.60% | $406.22M | 0.23% |
SHV | -9.49% | $20.08B | 0.15% |
DUSB | -9.24% | $1.15B | 0.15% |
BSMR | -9.20% | $232.67M | 0.18% |
SCMB | -9.08% | $618.54M | 0.03% |
CMF | -9.06% | $3.77B | 0.08% |
CMBS | -9.05% | $433.51M | 0.25% |
EQLS | -8.88% | $4.77M | 1% |
FLDR | -8.83% | $774.80M | 0.15% |
HYD | -8.67% | $3.45B | 0.32% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XPH | 34.03% | $164.53M | 0.35% |
RZV | 24.78% | $200.39M | 0.35% |
CALF | 23.67% | $5.12B | 0.59% |
PBE | 23.34% | $229.91M | 0.58% |
BSVO | 22.34% | $1.37B | 0.47% |
FBT | 22.26% | $1.11B | 0.56% |
VIOV | 22.21% | $1.21B | 0.1% |
RWJ | 21.86% | $1.58B | 0.39% |
SLYV | 21.52% | $3.73B | 0.15% |
IWC | 21.48% | $799.66M | 0.6% |
IJS | 21.18% | $6.41B | 0.18% |
EES | 20.75% | $572.93M | 0.38% |
PINK | 20.35% | $141.58M | 0.5% |
IWN | 20.32% | $10.95B | 0.24% |
DFSV | 20.32% | $4.18B | 0.31% |
IBB | 20.29% | $5.74B | 0.45% |
GSSC | 20.23% | $513.14M | 0.2% |
XRT | 20.17% | $259.06M | 0.35% |
ARKG | 19.63% | $963.54M | 0.75% |
XTN | 19.51% | $160.36M | 0.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FIVN | 48.39% | $2.05B | -55.48% | 0.00% |
PUBM | 47.08% | $450.82M | -60.67% | 0.00% |
AVD | 45.34% | $126.95M | -65.22% | 0.69% |
MITK | 39.43% | $377.33M | -40.47% | 0.00% |
MTUS | 36.06% | $557.93M | -40.23% | 0.00% |
RPAY | 32.86% | $500.82M | -45.51% | 0.00% |
NFE | 32.62% | $2.08B | -74.95% | 1.37% |
AQN | 32.31% | $4.06B | -17.50% | 5.96% |
SEE | 30.93% | $4.23B | -18.81% | 2.75% |
MTW | 30.58% | $308.70M | -37.38% | 0.00% |
FIGS | 30.48% | $732.97M | +0.45% | 0.00% |
RNG | 30.19% | $2.30B | -23.48% | 0.00% |
RWAY | 27.04% | $394.39M | -12.00% | 14.57% |
QNST | 26.98% | $1.02B | +5.94% | 0.00% |
CDXS | 26.83% | $207.92M | -24.62% | 0.00% |
EB | 26.60% | $201.56M | -59.27% | 0.00% |
SCL | 26.53% | $1.22B | -37.70% | 2.82% |
AVNS | 26.18% | $660.14M | -25.99% | 0.00% |
ARLO | 25.35% | $998.77M | -19.89% | 0.00% |
JYNT | 25.32% | $184.68M | -3.03% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DOCS | -38.28% | $10.64B | +119.84% | 0.00% |
QNTM | -36.29% | $15.34M | -81.65% | 0.00% |
G | -30.74% | $8.88B | +57.75% | 1.25% |
CARG | -29.45% | $3.05B | +29.38% | 0.00% |
ADMA | -27.90% | $4.61B | +201.55% | 0.00% |
TBRG | -26.57% | $406.32M | +209.57% | 0.00% |
ATSG | -22.89% | $1.48B | +74.09% | 0.00% |
EVH | -20.58% | $1.13B | -68.08% | 0.00% |
SG | -20.33% | $2.99B | +5.68% | 0.00% |
PRA | -18.63% | $1.19B | +87.40% | 0.00% |
IAG | -17.54% | $3.63B | +74.59% | 0.00% |
VHC | -17.29% | $34.33M | +31.92% | 0.00% |
HRTG | -15.99% | $463.10M | +38.43% | 0.00% |
NGL | -15.66% | $615.18M | -19.38% | 0.00% |
PAY | -15.49% | $3.40B | +24.37% | 0.00% |
EXPE | -12.89% | $21.61B | +27.34% | 0.24% |
RCEL | -12.87% | $202.97M | -46.32% | 0.00% |
CDLX | -12.41% | $98.44M | -86.15% | 0.00% |
SBS | -12.25% | $12.30B | +13.28% | 0.00% |
SLVM | -11.91% | $2.74B | +8.85% | 2.46% |
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
Yahoo
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at invest
SeekingAlpha
Impax Small Cap Fundâs equities posted their second consecutive positive quarter during a period that was dominated by the US presidential elections and its ramifications.
Yahoo
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
Yahoo
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issu
SeekingAlpha
Pacira BioSciences: Back On An Uptrend After Positive Developments